Consun Pharmaceutical Group Limited (HKG:1681)

Hong Kong · Delayed Price · Currency is HKD

13.32

+0.12 (0.91%)

Jun 18, 2026, 4:08 PM HKT

18.29% (1Y)

Market Cap	11.21B +28.2%
Revenue (ttm)	3.80B +15.2%
Net Income	1.20B +18.4%
EPS	1.40 +15.6%
Shares Out	841.55M
PE Ratio	9.50
Forward PE	7.81
Dividend	0.80 (6.01%)
Ex-Dividend Date	Jun 9, 2026

Volume	3,878,000
Open	13.18
Previous Close	13.20
Day's Range	12.94 - 13.35
52-Week Range	10.80 - 19.49
Beta	0.47
Analysts	Buy
Price Target	23.75 (+78.3%)
Earnings Date	Aug 20, 2026

About HKG:1681

Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiol... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1997

Employees 3,115

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 1681

Full Company Profile

Financial Performance

In 2025, HKG:1681's revenue was 3.42 billion, an increase of 15.17% compared to the previous year's 2.97 billion. Earnings were 1.08 billion, an increase of 18.41%.

Financial numbers in CNY Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 1681 stock is "Buy." The 12-month stock price target is $23.75, which is an increase of 78.30% from the latest price.

Price Target

$23.75

(78.30% upside)

Analyst Consensus: Buy

Stock Forecasts